Skip to main content

Table 3 Univariate and multivariate analyses for overall survival of the entire cohort

From: The role of muscle depletion and visceral adiposity in HCC patients aged 65 and over undergoing TACE

 

Univariate analysis

Multivariate analysis

 

HR (95% CI)

P value

HR (95% CI)

P value

Age (year)

1.060 (1.030–1.090)

< 0.001

1.057 (0.946–1.024)

< 0.001

Sex

0.982 (0.726–1.330)

0.905

  

BMI (kg/m2)

0.983 (0.942–1.030)

0.446

  

Diabetes

1.170 (0.871–1.570)

0.295

  

Hypertension

0.759 (0.573–1.010)

0.056

  

Cardiovascular attack

1.330 (0.703–2.510)

0.381

  

Other malignancy

1.400 (0.810–2.410)

0.229

  

Renal failure on dialysis

1.920 (0.984–3.760)

0.056

  

Alcohol

0.937 (0.711–1.240)

0.645

  

Smoking

0.922 (0.700–1.220)

0.565

  

Etiology

 

0.002

  

 Hepatitis B

1

–

  

 Hepatitis C

1.802 (1.295–2.507)

< 0.001

  

 Others

1.314 (0.917–1.883)

0.137

  

Variceal bleeding

1.760 (0.437–7.110)

0.426

  

Ascites

1.910 (1.060–3.440)

0.030

  

MELD score

1.100 (1.050–1.160)

< 0.001

1.078 (0.928–1.009)

0.027

Number of tumors

1.250 (0.947–1.650)

0.116

  

Size of tumor (cm)

1.060 (1.020–1.110)

0.006

1.083 (0.923–1.026)

0.004

Albumin (g/dL)

0.467 (0.358–0.611)

< 0.001

0.523 (1.912–0.383)

< 0.001

Platelet (uL)

0.996 (0.993–0.999)

0.004

0.996 (1.004–0.993)

0.006

BCLC

 

0.022

 

0.015

 stage 0

1

–

1

–

 stage A

1.691 (1.012–2.824)

0.045

1.711 (0.585–1.012)

0.045

 stage B

2.062 (1.221–3.480)

0.007

2.003 (0.499–1.148)

0.014

Infiltrative type of HCC

1.210 (0.300–4.870)

0.791

  

Serum AFP (ng/mL)

1.000 (1.000–1.000)

0.573

  

MDVA

1.501 (1.118–2.014)

0.007

1.515 (0.660–1.112)

0.009

Objective tumor response

0.614 (0.448–0.843)

0.003

0.680 (1.471–0.488)

0.023

  1. AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; BMI, body mass index; HCC, hepatocellular carcinoma; MDVA, muscle depletion with visceral adiposity; MELD, model for end-stage liver disease